{
  "id": "5c73ad057c78d6947100008f",
  "type": "list",
  "question": "List two drugs that are included in the Akynzeo pill?",
  "ideal_answer": "Akynzeo is an oral fixed combination of netupitant and palonosetron that is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25516691",
    "http://www.ncbi.nlm.nih.gov/pubmed/26613606",
    "http://www.ncbi.nlm.nih.gov/pubmed/29547597",
    "http://www.ncbi.nlm.nih.gov/pubmed/27473611"
  ],
  "snippets": [
    {
      "text": "OBJECTIVES: To review the latest antiemetic guideline recommendations and provide an update on the use of NEPA, a fixed combination antiemetic composed of the neurokinin-1 receptor antagonist (RA) netupitant and the 5-hydroxytryptamine-3 RA palonosetron (Akynzeo\u00ae).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29547597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An oral fixed combination of netupitant/palonosetron (NEPA; Akynzeo(\u00ae)) with >85% antiemetic efficacy is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An oral fixed combination of netupitant/palonosetron (NEPA; Akynzeo(\u00ae)) is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.An oral fixed combination of netupitant/palonosetron (NEPA; Akynzeo(\u00ae)) is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613606",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pharmaceutical approval update.Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516691",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "netupitant, palonosetron"
}